A. Bucko

发表

Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study.

Sewon Kang, D. Thiboutot, J. Weiss, 2007, Journal of the American Academy of Dermatology.

Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis.

J. Jorizzo, A. Bucko, D. Stough, 2002, Cutis.

Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail.

B. Elewski, J. Leyden, Sewon Kang, 1998, Journal of the American Academy of Dermatology.

Pharmacokinetics of three doses of once-weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail.

N. Konnikov, A. Bucko, N. Levine, 1998, Journal of the American Academy of Dermatology.

Pharmacokinetics of three once-weekly dosages of fluconazole (150, 300, or 450 mg) in distal subungual onychomycosis of the fingernail.

J. Leyden, S. Kang, L. Drake, 1998, Journal of the American Academy of Dermatology.

Randomized, double-blind, multicenter comparison of oral cefditoren 200 or 400 mg BID with either cefuroxime 250 mg BID or cefadroxil 500 mg BID for the treatment of uncomplicated skin and skin-structure infections.

A. Bucko, S. L. Kidd, B. J. Hunt, 2002, Clinical therapeutics.

Efficacy and safety of once-daily luliconazole 1% cream in patients ≥12 years of age with interdigital tinea pedis: a phase 3, randomized, double-blind,vehicle-controlled study.

J. Olin, A. Bucko, T. Jones, 2014, Journal of drugs in dermatology : JDD.

Efinaconazole solution in the treatment of toenail onychomycosis: a phase 2, multicenter, randomized, double-blind study.

J. Olin, A. Bucko, E. Tschen, 2013, Journal of drugs in dermatology : JDD.

Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail.

J. Leyden, S. Kang, L. Drake, 1998, Journal of the American Academy of Dermatology.

Fluorouracil cream 0.5% for the treatment of actinic keratoses on the face and anterior scalp: interim results of an 18-month open-label study.

A. Bucko, D. Stough, E. Rafal, 2008, The Journal of clinical and aesthetic dermatology.

The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis.

J. Ocampo-Candiani, A. Bucko, T. Jones, 2014, Journal of drugs in dermatology : JDD.

Efficacy and Safety of Subantimicrobial Dose, Modified-Release Doxycycline 40 mg Versus Doxycycline 100 mg Versus Placebo for the treatment of Inflammatory Lesions in Moderate and Severe Acne: A Randomized, Double-Blinded, Controlled Study.

A. Bucko, A. Moore, M. Ling, 2015, Journal of drugs in dermatology : JDD.

Assessment of HPA-Axis Suppression with Fluticasone Cream 0.05% in Patients with Extensive Psoriasis or Eczema

A. Bucko, E. Tschen, 1998, Clinical drug investigation.

Fluorouracil cream 0.5% for actinic keratoses on multiple body sites: an 18-month open-label study.

A. Bucko, D. Stough, E. Rafal, 2010, Cutis.

A 6‐month maintenance therapy with adapalene‐benzoyl peroxide gel prevents relapse and continuously improves efficacy among patients with severe acne vulgaris: results of a randomized controlled trial

J. Fowler, Y. Poulin, N. Kerrouche, 2011, The British journal of dermatology.

Pharmacokinetics of ingenol mebutate gel under maximum use conditions in large treatment areas

A. Bucko, J. Villumsen, M. Jarratt, 2018, The Journal of dermatological treatment.

Safety of a novel gel formulation of clindamycin phosphate 1.2%-tretinoin 0.025%: results from a 52-week open-label study.

J. Fowler, A. Bucko, L. Kircik, 2008, Cutis.

Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: First of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-controlled Trials.

J. Weiss, A. Bucko, S. Grekin, 2016, Journal of drugs in dermatology : JDD.

Clindamycin phosphate 1% gel in acne vulgaris

A. Bucko, D. Whiting, R. Rizer, 2001, Advances in therapy.

A 6‐month maintenance therapy with adapalene‐benzoyl peroxide gel prevents relapse and continuously improves efficacy among patients with severe acne vulgaris: results of a randomized controlled trial

N. Kerrouche, A. Bucko, S. Kempers, 2011, The British journal of dermatology.